Morpholine KECH-18D Restores Drug Sensitivity and Differentially Modulates Efflux Phenotypes in Cisplatin- and Paclitaxel-Resistant Cervical Cancer Cells
DOI:
https://doi.org/10.31557/APJCB.2026.11.3.705Keywords:
Chemoresistance, Cisplatin-resistant cells, Paclitaxel-resistant cells, Morpholine KECH-18D, Drug efflux modulationAbstract
Background: Chemoresistance represents a major obstacle in cancer therapy, often associated with enhanced drug efflux. This study aimed to generate and characterize cisplatin-resistance in C-33A cells (C-33A RCDDP), and included, for comparison, a previously established paclitaxel-resistant subline (C-33A RPTX) overexpressing transporters, such as ABCB1, ABCG4, and ABCC8. In addition, we assessed whether the morpholine KECH-18D could restore drug sensitivity by enhancing intracellular drug accumulation.
Materials and Methods: C-33A RCDDP cells were developed by stepwise cisplatin (CDDP) exposure. Cytotoxicity assays of nine morpholines were carried out to identify structural determinants of anticancer activity in the C-33A cell line. Combinatorial assays with morpholine KECH-18D and CDDP or paclitaxel (PTX) were performed to determine whether KECH-18D chemosensitizes and retains the drug in C-33A RCDDP and C-33A RPTX cells.
Results: C-33A RCDDP cells exhibited a 4.7-fold increase in CDDP resistance. C-33A RCDDP and C-33A RPTX cells both displayed cross-resistance patterns, but C-33A RTPX cells retained lower levels of the drug than C-33A RCDDP cells. Furthermore, KECH-18D maintained strong cytotoxicity against chemoresistant cell lines and enhanced the cytotoxicity of CDDP and PTX against them. Notably, KECH-18D increased drug accumulation in C-33A RCDDP cells in a time-dependent manner, but not in C-33A RPTX cells.
Conclusion: In summary, C-33A RCDDP and C-33A RPTX cells developed different levels, and possibly mechanisms, of resistance. Because the morpholine KECH-18D resulted highly cytotoxic in both parental and chemoresistant cells, enhanced drug retention in C-33A RCDDP cells and increased the toxicity of CDDP or PTX in chemoresistant cells, KECH-18D is a promising scaffold for overcoming multidrug resistance by selectively modulating drug efflux-related and -unrelated phenotypes, though further studies are necessary to deep its mechanisms of action.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Asian Pacific Journal of Cancer Biology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).





3.jpg)





